Shields Matthew 4

What Happened

• Matthew Shields, EVP, Global Operations of Teva Pharmaceutical Industries (TEVA), received a grant of 33,424 restricted share units (RSUs) on March 4, 2026. The grant is recorded at $0.00 per unit on the Form 4 (derivative award). This is a compensation award (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: March 4, 2026; Form 4 filed March 6, 2026.
• Award: 33,424 restricted share units (RSUs) — reported at $0.00 per unit (derivative grant).
• Vesting schedule: 8,356 RSUs vest on each of March 4, 2027; March 4, 2028; March 4, 2029; and March 4, 2030 (footnote F2).
• Settlement mechanics: Each RSU represents a contingent right to receive one ordinary share (or, at the Compensation Committee’s option, cash equal to the share value) at settlement (footnote F1).
• ADS note: Ordinary Shares may be represented by American Depositary Shares (each currently represents one Ordinary Share) (footnote F3).
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context

• This is a standard executive compensation grant (RSUs) rather than a market buy or sell; such grants are routine and tied to retention or performance objectives. Derivative RSUs convert to shares or cash upon vesting/settlement per the terms noted above.